PE20180499A1 - UNION TO TAU ANTIBODIES - Google Patents
UNION TO TAU ANTIBODIESInfo
- Publication number
- PE20180499A1 PE20180499A1 PE2017002758A PE2017002758A PE20180499A1 PE 20180499 A1 PE20180499 A1 PE 20180499A1 PE 2017002758 A PE2017002758 A PE 2017002758A PE 2017002758 A PE2017002758 A PE 2017002758A PE 20180499 A1 PE20180499 A1 PE 20180499A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- union
- tau antibodies
- cdr1
- cdr2
- Prior art date
Links
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
SE REFIERE A UN ANTICUERPO DE UNION A TAU AISLADO O FRAGMENTO DE UNION DEL MISMO, EL CUAL COMPRENDE: A) UNA REGION VARIABLE DE CADENA LIGERA DE SEC ID N°:13, QUE COMPRENDE UNA CDR1 DE SEC ID N°: 1, UNA CDR2 DE SEC ID N°: 2, Y UNA CDR3 DE SEC ID N°: 3; Y B) UNA REGION VARIABLE DE CADENA PESADA DE SEC ID N°:16, QUE COMPRENDE UNA CDR1 DE SEC ID N°: 4, UNA CDR2 DE SEC ID N°: 5, Y UNA CDR3 DE SEC ID N°: 6. TAMBIEN SE REFIERE A UN METODO PARA PRODUCIR EL ANTICUERPO. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER O PARALISIS SUPRANUCLEAR PROGRESIVAIT REFERS TO AN ISOLATED TAU BINDING BODY OR UNION FRAGMENT THEREOF, WHICH INCLUDES: A) A LIGHT CHAIN VARIABLE REGION OF SEQ ID N °: 13, WHICH INCLUDES A CDR1 OF SEQ ID N °: 1, A CDR2 OF SEQ ID NO: 2, AND A CDR3 OF SEQ ID NO: 3; AND B) A HEAVY-CHAIN VARIABLE REGION OF SEQ ID N °: 16, INCLUDING A CDR1 OF SEQ ID N °: 4, A CDR2 OF SEQ ID N °: 5, AND A CDR3 OF SEQ ID N °: 6. ALSO REFERS TO A METHOD OF PRODUCING THE ANTIBODY. SUCH ANTIBODY IS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE OR PROGRESSIVE SUPRANUCLEAR PARALYSIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15175519 | 2015-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20180499A1 true PE20180499A1 (en) | 2018-03-09 |
Family
ID=53524638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002758A PE20180499A1 (en) | 2015-07-06 | 2016-07-05 | UNION TO TAU ANTIBODIES |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US10344081B2 (en) |
| EP (1) | EP3319984A1 (en) |
| JP (1) | JP6937289B2 (en) |
| KR (1) | KR102742965B1 (en) |
| CN (1) | CN107849105B (en) |
| AR (1) | AR105266A1 (en) |
| AU (1) | AU2016289753C1 (en) |
| CA (1) | CA2991264C (en) |
| CL (1) | CL2018000042A1 (en) |
| CO (1) | CO2017012974A2 (en) |
| EA (1) | EA036821B1 (en) |
| EC (1) | ECSP18000844A (en) |
| IL (1) | IL256687B (en) |
| MA (2) | MA42380A (en) |
| MX (1) | MX2017015908A (en) |
| PE (1) | PE20180499A1 (en) |
| PH (1) | PH12017502180A1 (en) |
| TN (1) | TN2017000543A1 (en) |
| TW (1) | TWI748954B (en) |
| UY (1) | UY36774A (en) |
| WO (1) | WO2017005732A1 (en) |
| ZA (1) | ZA201708128B (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20152004A1 (en) | 2013-03-13 | 2016-02-07 | Prothena Biosciences Ltd | IMMUNOTHERAPY TAU |
| NZ775762A (en) | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| KR102770650B1 (en) | 2015-07-06 | 2025-02-19 | 유씨비 바이오파마 에스알엘 | Tau binding antibody |
| US10344081B2 (en) | 2015-07-06 | 2019-07-09 | Ucb Biopharma Sprl | Tau-binding antibodies |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| CA3022515A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| TW202328181A (en) | 2016-12-07 | 2023-07-16 | 美商建南德克公司 | Anti-tau antibodies and methods of use |
| CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP4491234A3 (en) | 2017-02-08 | 2025-04-09 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| AU2018221049A1 (en) | 2017-02-17 | 2019-09-19 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| DK3582806T5 (en) | 2017-02-20 | 2024-09-02 | Dragonfly Therapeutics Inc | PROTEINS THAT BIND HER2, NKG2D, AND CD16 |
| JP2018139530A (en) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | Humanized antibody for treating or preventing dementia and production method therefor and therapeutic agent or prophylactic agent for dementia using same |
| CU24636B1 (en) | 2017-05-02 | 2022-12-12 | Prothena Biosciences Ltd | ANTIBODIES RECOGNIZING TAU IN RESIDUES 257-271 OR 320-334 OF SEQ ID NO: 1 |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| US12384847B2 (en) | 2018-02-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen |
| EP3749346B1 (en) | 2018-02-08 | 2024-07-10 | Dragonfly Therapeutics, Inc. | Antibody variable domain combinations targeting the nkg2d receptor |
| EP3755721A4 (en) | 2018-02-20 | 2021-12-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| AU2019318087B2 (en) | 2018-08-08 | 2025-09-18 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD 16 and a tumor-associated antigen |
| EA202091888A1 (en) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR |
| AR114544A1 (en) | 2018-08-08 | 2020-09-16 | Dragonfly Therapeutics Inc | MULTI-SPECIFIC BINDING PROTEINS BINDING BCMA, NKG2D AND CD16, AND METHODS OF USE |
| EP3894438A1 (en) | 2018-12-13 | 2021-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New anti tau svqivykpv epitope single domain antibody |
| CA3131531A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CA3179914A1 (en) * | 2020-04-08 | 2021-10-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and uses thereof |
| MX2022013944A (en) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and clec12a. |
| US11702467B2 (en) | 2020-06-25 | 2023-07-18 | Merck Sharp & Dohme Llc | High affinity antibodies targeting tau phosphorylated at serine 413 |
| US20240101654A1 (en) * | 2020-12-29 | 2024-03-28 | Neurimmune Ag | Human anti-tau antibodies |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN120019071A (en) | 2022-09-15 | 2025-05-16 | 沃雅戈治疗公司 | TAU-binding compounds |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025147472A1 (en) * | 2024-01-02 | 2025-07-10 | Phanes Therapeutics, Inc. | Anti-611-ctf p95her2 antibodies and uses thereof |
| WO2025196217A1 (en) | 2024-03-21 | 2025-09-25 | UCB Biopharma SRL | Treatment of tauopathies with tau-binding antibodies |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| WO1993008302A1 (en) | 1991-10-25 | 1993-04-29 | Itt Automotive Europe Gmbh | Monoclonal antibodies directed against the microtubule-associated protein tau |
| US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
| US6010913A (en) | 1992-12-14 | 2000-01-04 | N.V. Innogenetics S.A. | Isolated human tau peptide |
| ES2270421T3 (en) | 1993-12-21 | 2007-04-01 | Innogenetics N.V. | SPECIFIC MONOCLONAL ANTIBODIES FOR PHF-TAU, HYBRIDOMES THAT SECRET THEMSELVES, ANTIGEN RECOGNITION FOR THESE ANTIBODIES AND THEIR APPLICATIONS. |
| US6121003A (en) | 1994-07-29 | 2000-09-19 | Innogentics N.V. | Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| ES2551439T5 (en) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fab fragments of modified antibodies |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| CN1721437A (en) * | 2004-07-13 | 2006-01-18 | 中南大学 | A kind of polypeptide antigen and antibody related to Tau protein |
| BRPI0615026A8 (en) | 2005-08-19 | 2018-03-06 | Abbott Lab | double variable domain immunoglobulin and its uses |
| AU2006326284B2 (en) | 2005-12-12 | 2013-06-06 | Ac Immune S.A. | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| ES2622460T3 (en) | 2007-09-26 | 2017-07-06 | Ucb Biopharma Sprl | Fusions of antibodies with double specificity |
| CA2719400C (en) * | 2008-03-26 | 2017-11-14 | Epitomics, Inc. | Anti-vegf antibody |
| CN101307108B (en) * | 2008-06-25 | 2012-04-04 | 南京川博生物技术有限公司 | Anti-phosphorylated Tau protein antibody and application thereof in determination of AD abnormal phosphorylated Tau protein level |
| EA201100527A1 (en) | 2008-09-26 | 2011-10-31 | Юсб Фарма С.А. | BIOLOGICAL PRODUCTS |
| UA107571C2 (en) | 2009-04-03 | 2015-01-26 | PHARMACEUTICAL COMPOSITION | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EP2440234A4 (en) | 2009-06-10 | 2013-11-06 | Univ New York | IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS |
| RU2518291C2 (en) | 2009-07-30 | 2014-06-10 | Пфайзер Вэксинс ЭлЭлСи | Antigen tau-peptides and their application |
| EP2475682B1 (en) | 2009-09-10 | 2018-01-31 | UCB Biopharma SPRL | Multivalent antibodies |
| MX345092B (en) | 2010-10-11 | 2017-01-17 | Univ Zuerich | Human anti-tau antibodies. |
| ES2714692T3 (en) | 2011-01-31 | 2019-05-29 | Tau Bio Logic Corp | Tauopathies treatment |
| GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| MX347505B (en) | 2011-09-19 | 2017-04-28 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease. |
| MX351502B (en) | 2011-11-11 | 2017-10-18 | Ucb Pharma Sa | Albumin binding antibodies and binding fragments thereof. |
| HRP20191342T1 (en) * | 2011-12-20 | 2019-11-01 | Janssen Biotech Inc | Anti-phf-tau antibodies and their uses |
| AU2013243861A1 (en) | 2012-04-05 | 2014-10-23 | Ac Immune S.A. | Humanized Tau antibody |
| SG10201913370PA (en) | 2012-07-03 | 2020-03-30 | Univ Washington | Antibodies to tau |
| WO2014016737A1 (en) | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
| WO2014028777A2 (en) | 2012-08-16 | 2014-02-20 | Ipierian, Inc. | Methods of treating a tauopathy |
| CN111205368B (en) | 2012-12-21 | 2023-05-09 | 比奥根Ma公司 | Human anti-TAU antibodies |
| PE20152004A1 (en) | 2013-03-13 | 2016-02-07 | Prothena Biosciences Ltd | IMMUNOTHERAPY TAU |
| MX374811B (en) | 2013-03-15 | 2025-03-06 | Ac Immune Sa | ANTI-TAU ANTIBODIES AND METHODS OF USE. |
| RS60031B1 (en) | 2013-12-20 | 2020-04-30 | Hoffmann La Roche | Humanized anti-tau(ps422) antibodies and methods of use |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| TWI669314B (en) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | Antibodies to tau and uses thereof |
| NZ775762A (en) | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| US10344081B2 (en) | 2015-07-06 | 2019-07-09 | Ucb Biopharma Sprl | Tau-binding antibodies |
| KR102770650B1 (en) | 2015-07-06 | 2025-02-19 | 유씨비 바이오파마 에스알엘 | Tau binding antibody |
| JO3711B1 (en) | 2015-07-13 | 2021-01-31 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
-
2016
- 2016-07-05 US US15/742,070 patent/US10344081B2/en active Active
- 2016-07-05 CN CN201680039813.9A patent/CN107849105B/en active Active
- 2016-07-05 AU AU2016289753A patent/AU2016289753C1/en active Active
- 2016-07-05 WO PCT/EP2016/065809 patent/WO2017005732A1/en not_active Ceased
- 2016-07-05 MX MX2017015908A patent/MX2017015908A/en unknown
- 2016-07-05 JP JP2018500422A patent/JP6937289B2/en active Active
- 2016-07-05 PE PE2017002758A patent/PE20180499A1/en unknown
- 2016-07-05 MA MA042380A patent/MA42380A/en unknown
- 2016-07-05 TN TNP/2017/000543A patent/TN2017000543A1/en unknown
- 2016-07-05 MA MA41669A patent/MA41669A1/en unknown
- 2016-07-05 EA EA201890169A patent/EA036821B1/en not_active IP Right Cessation
- 2016-07-05 EP EP16736072.6A patent/EP3319984A1/en active Pending
- 2016-07-05 CA CA2991264A patent/CA2991264C/en active Active
- 2016-07-05 KR KR1020187003686A patent/KR102742965B1/en active Active
- 2016-07-06 AR ARP160102044A patent/AR105266A1/en unknown
- 2016-07-06 TW TW105121454A patent/TWI748954B/en active
- 2016-07-06 UY UY0001036774A patent/UY36774A/en not_active Application Discontinuation
-
2017
- 2017-11-29 PH PH12017502180A patent/PH12017502180A1/en unknown
- 2017-11-29 ZA ZA2017/08128A patent/ZA201708128B/en unknown
- 2017-12-18 CO CONC2017/0012974A patent/CO2017012974A2/en unknown
-
2018
- 2018-01-01 IL IL256687A patent/IL256687B/en unknown
- 2018-01-05 CL CL2018000042A patent/CL2018000042A1/en unknown
- 2018-01-05 EC ECIEPI2018844A patent/ECSP18000844A/en unknown
-
2019
- 2019-07-01 US US16/458,217 patent/US10906966B2/en active Active
-
2020
- 2020-12-29 US US17/136,440 patent/US11746145B2/en active Active
-
2023
- 2023-06-30 US US18/344,930 patent/US20230331833A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20180499A1 (en) | UNION TO TAU ANTIBODIES | |
| PE20191208A1 (en) | ANTI-CD73 ANTIBODIES AND USES OF THEM | |
| CL2019001926A1 (en) | Anti-tigit antibodies and antigen-binding fragments; pharmaceutical composition comprising them; polynenucleotide encoding said antibody; vector comprising them, host cell; method of producing said antibody or antigen-binding fragment thereof; and use in the treatment of cancer. (Divisional Application 310-2017). | |
| PE20190970A1 (en) | ANTI-CD40 ANTIBODIES AND THEIR USES | |
| PE20190737A1 (en) | ANTI-CD27 ANTIBODIES | |
| PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
| PE20180481A1 (en) | UNION TO TAU ANTIBODIES | |
| EA201991577A1 (en) | NEW ANTIBODIES AGAINST THE HUMAN TRANSFERRIN RECEPTOR, ABLE TO BREAK THE HEMATOENCEPHALIC BARRIER | |
| EA201892793A1 (en) | ANTI-HLA-G SPECIFIC ANTIBODIES | |
| EA201890145A1 (en) | ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION | |
| PE20171654A1 (en) | COMPOSITIONS AND METHODS USED TO INCREASE IMMUNE RESPONSE AND IN CANCER THERAPY | |
| EA201890305A1 (en) | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | |
| NZ727024A (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
| PH12017500890A1 (en) | Antibody drug conjugates | |
| PE20190208A1 (en) | ANTIBODIES THAT RECOGNIZE TAU | |
| PE20150002A1 (en) | ANTI-FCRN ANTIBODIES | |
| PE20131209A1 (en) | ANTI-FAP ANTIBODIES | |
| PH12015501505B1 (en) | Antibodies that bind to tl1a and their uses | |
| PE20211293A1 (en) | MONOCLONAL ANTIBODIES ANTAGONISTS AGAINST CD40 AND THEIR USES | |
| NZ631007A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
| PE20161571A1 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE | |
| PE20140247A1 (en) | ANTI-CD38 ANTIBODIES | |
| PH12017501522B1 (en) | Antibodies to tau and uses thereof | |
| PE20161210A1 (en) | ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE | |
| MX2023007840A (en) | Monovalent anti-properdin antibodies and antibody fragments. |